	US 12,109,195 B2
	Compositions and methods for treatment of vaginal infections
Mark C. Faulkner, Madison, TN (US); and Deeannah Seymour, Franklin, TN (US)
Assigned to Vireo Systems, Inc., Madison, TN (US)
Filed by Vireo Systems, Inc., Madison, TN (US)
Filed on Jun. 30, 2021, as Appl. No. 17/363,193.
Claims priority of provisional application 63/045,897, filed on Jun. 30, 2020.
Prior Publication US 2021/0401806 A1, Dec. 30, 2021
Int. Cl. A61K 31/41 (2006.01); A61K 9/00 (2006.01); A61K 9/02 (2006.01); A61K 31/194 (2006.01); A61K 31/4168 (2006.01); A61K 31/7016 (2006.01); A61K 31/702 (2006.01); A61K 31/733 (2006.01); A61K 33/22 (2006.01); A61K 35/747 (2015.01); A61P 31/04 (2006.01)

CPC A61K 31/4168 (2013.01) [A61K 9/0036 (2013.01); A61K 9/02 (2013.01); A61K 31/194 (2013.01); A61K 31/7016 (2013.01); A61K 31/702 (2013.01); A61K 31/733 (2013.01); A61K 33/22 (2013.01); A61K 35/747 (2013.01); A61P 31/04 (2018.01)]

15 Claims

1. A method for inhibiting growth of one or more species of bacteria associated with bacterial vaginosis, comprising:

preparing a composition consisting of protonated creatinine, a protonated creatinine salt, or combinations thereof, wherein the protonated creatinine, protonated creatinine salt, or combination thereof is present in the composition in an amount of about 10 mg to about 300 mg; and

subjecting the one or more species of bacteria to the composition.